|
市場調查報告書
免疫／發炎之生產線：戰略性回顧
The Immune/Inflammatory Pipeline: A Strategic Review
|
免疫／發炎之生產線：戰略性回顧 是由出版商Decision Resources, Inc.在2009年05月所出版的。
這份英文市場調查報告書包含37 Pages 價格從美金3450起跳。
現今的免疫／發炎治療的藥品開發約有375種之候補藥品，並由約250家之企業從事開發。同一市場中在2003∼2008年間達到了穩健的成長。因為在免疫／發炎疾病的治療領域裡收益很高，今後之後續動向也十分受人矚目。
本報告由2008年中免疫疾病／發炎性疾病治療藥物之銷售、開發中新藥物與從事企業之檔案、規範趨勢等交織而成，並匯整以下列摘要形式闡述。
實施概要
簡介
免疫疾病／發炎性疾病生產線
- 因應尚未滿足之需求之新興藥劑
- 開發免疫疾病／發炎性疾病免治療藥物之企業
- 現今主要企業
- Novartis
- GlaxoSmithKline
- Pfizer
免疫疾病／發炎性疾病市場相關之課題與機會
- 現今市場領導產品為新興治療帶來的阻礙
- 但各式問題點為新興藥劑形成機會
新興藥劑今後之預測
- 現今之市場統計
- 生產線與企業
- 合併與收購會持續震盪市場嗎
- 領導市場之企業會持續獨佔嗎
圖表
Abstract
Introduction
The current immune/inflammatory pipeline is over 375 drugs strong, with
approximately 250 companies involved in these agents' development. Yet,
despite this robust pipeline size, Decision Resources analysts do not believe
that any one agent in development will significantly alter the way physicians
treat their patients with immune/inflammatory disorders. Nonetheless,
opportunities exist for companies that develop treatments for specific unmet
needs in this therapeutic area. While these opportunities will not yield the
kind of cross-indication blockbuster returns previously seen in this
therapeutic area, investing R&D money in the immune/inflammatory area still
seems worthwhile.
Questions Answered in This Report
- The immune/inflammatory market experienced steady growth from 2003 through
2008. What drug classes contributed most to this steady increase in sales?
What other factors play a role in market growth in this therapeutic area?
- The failure rate of current biologics for rheumatoid arthritis (RA) and
similar indications is high enough to justify the need for more-efficacious
treatments. Does the pipeline feature novel agents with potential for
higher efficacy than current agents? Which indications within this therapeutic
area are drawing the most interest from developers?
- The immune/inflammatory therapeutic area is lucrative and will likely
continue to be so in the future. Which companies are the current market
leaders? Which companies are attempting to enter, grow, or defend their
position in this market?
- Replicating the success of today' s immune/inflammatory agents presents a
challenge to developers of novel treatments. How do regulatory requirements
complicate R&D efforts? How can drug developers working in this area maximize
their chances of success?
Scope
- 2008 market: 2008 sales; leading drug classes; market-leading
companies; commercial position of leading agents.
- The immune/inflammatory disease pipeline: Number of agents in
development; disease focus; active companies; profiles of Novartis,
GlaxoSmithKline, and Pfizer; mechanisms of action; company type; phase
analysis; novel formulations versus reformulations; smallmolecule drugs versus
biologics.
- Immune/inflammatory diseases focused on in this report: Ankylosing
spondylitis; asthma; chronic obstructive pulmonary disease (COPD); Crohn' s
disease (CD); psoriasis; psoriatic arthritis; rheumatoid arthritis (RA);
Sjogren' s syndrome; systemic lupus erythematosus (SLE); ulcerative colitis
(UC).
- Challenges in immune/inflammatory diseases: Regulatory issues;
challenging first-line therapies.
- Opportunities in immune/inflammatory diseases: Working to tap unmet
needs; gaining access to niche indications.
Mentioned in This Report
- Abbott Laboratories
- Amgen
- Array BioPharma
- AstraZeneca
- Boehringer Ingelheim
- Centocor
- CombinatoRx
- Dong-A Pharmaceutical
- Eisai
- Eli Lilly
- Genentech
- GlaxoSmithKline
- Johnson & Johnson
- Medimmune
- Merck & Co.
- Merck Serono
- Mitsubishi Tanabe Pharma
- Novartis
- Pfizer
- Roche
- Schering-Plough
- Takeda
- UCB
- Wyeth
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- The Immune/Inflammatory Disease Pipeline
- Emerging Agents Targeting Diseases with Unmet Needs
- Companies Developing Immune/Inflammatory Disease Agents
- Current Market-Leading Companies
- Novartis
- GlaxoSmithKline
- Pfizer
- Challenges and Opportunities in the Immune/Inflammatory Disease Market.
- Current Market-Leading Products Pose a High Hurdle for Emerging
Therapies......
- ......But Also Leave Gaps That Provide Opportunities for Emerging Agents
- Opportunities in Rheumatoid Arthritis.
- Opportunities in Chronic Obstructive Pulmonary Disease
- Opportunities in Systemic Lupus Erythematosus.
- Outlook for Emerging Agents
- Current Market Statistics
- Pipelines and Companies
- Will Mergers & Acquisitions Continue to Move the Market?
- Will Market-Leading Companies Continue to Dominate?
Tables
- 1. Descriptions of Inflammatory and Autoimmune Disorders
- 2. Drug Classes Commonly Used to Treat Cardiovascular Diseases
- 3. Key Unmet Needs in Common Immune/Inflammatory Diseases
- 4. Immune/Inflammatory Market-Leading Companies, 2008
- 5. Top-Selling Immune/Inflammatory Drugs, 2008
- 6. Novartis' s Immune/Inflammatory Pipeline
- 7. GlaxoSmithKline' s Immune/Inflammatory Pipeline
- 8. Pfizer' s Immune/Inflammatory Pipeline
- 9. Wyeth' s Immune/Inflammatory Pipeline
Figures
- 1. Percentage of Novel and Non-Novel Molecules in the Immune/Inflammatory
Pipeline
- 2. Immune/Inflammatory Pipeline by Development Phase
- 3. Immune/Inflammatory Pipeline by Disease
- 4. Percentage of Immune/Inflammatory Pipeline Drugs by Type
- 5. Drugs Targets, by Number, of Immune/Inflammatory Pipeline Drugs
- 6. Development Activity by Company Size
- 7. Companies with Multiple Immune/Inflammatory Drugs in Development
- 8. Companies with Leading Immune/Inflammatory Pipelines, Number of Agents
by Disease
- 9. GlaxoSmithKline' s Immune/Inflammatory Franchise Sales, 2008
- 10. Abbott Laboratories' Immune/Inflammatory Franchise Sales, 2008
- 11. Immune/Inflammatory Sales by Therapy Area, 2003-2008
- 12. Immune/Inflammatory Disease Market Growth by Region, 2003-2008.
- 13. Worldwide Sales of Immune/Inflammatory Drug Classes, 2008
|
